Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 9/20 | 0.42 |
| ▸ | CNR1 | P21554 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 1/20 | 0.37 |
| ▸ | CA9 | Q16790 | 1/20 | 0.37 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12161541 | 0.94 | EPHX2 (0.43) | EPHX2CNR1SMN1; SMN2KMT2AABCB1 | |
| SCHEMBL9922261 | 0.91 | EPHX2 (0.43) | EPHX2CNR1SMN1; SMN2KMT2AABCB1 | |
| SCHEMBL12177178 | 0.91 | EPHX2 (0.43) | EPHX2CNR1SMN1; SMN2CA1CA2 | |
| SCHEMBL9922601 | 0.88 | EPHX2 (0.41) | EPHX2CNR1 | |
| SCHEMBL9922974 | 0.86 | MAPT (0.39) | SMN1; SMN2CA1CA2CA9KMT2A | |
| SCHEMBL9922264 | 0.84 | P2RY12 (0.45) | EPHX2CNR1CA1CA2 | |
| SCHEMBL12177207 | 0.84 | EPHX2 (0.41) | EPHX2CNR1CA1CA2CA9 | |
| SCHEMBL9922427 | 0.84 | EPHX2 (0.42) | EPHX2CNR1SMN1; SMN2KMT2A | |
| SCHEMBL9923107 | 0.82 | EPHX2 (0.40) | EPHX2CNR1SMN1; SMN2KMT2A | |
| SCHEMBL9922814 | 0.81 | EPHX2 (0.46) | EPHX2CNR1SMN1; SMN2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120149688-A1 | PLATELET ADP RECEPTOR INHIBITORS | PORTOLA PHARMACEUTICALS, INC. (US) | 2012-06-14 | — | — | US | disclosed |
| US-8067428-B2 | Platelet ADP receptor inhibitors | PORTOLA PHARMACEUTICALS, INC. (US) | 2011-11-29 | — | — | US | disclosed |
| US-20100234350-A1 | PLATELET ADP RECEPTOR INHIBITORS | PORTOLA PHARMACEUTICALS, INC. (US) | 2010-09-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100234350-A1 | PLATELET ADP RECEPTOR INHIBITORS | TBXA2R, GP6, P2RY6 | EPHX2 3275/4885CNR1 264/4885SMN1; SMN2 3108/4885 |
| US-20120149688-A1 | PLATELET ADP RECEPTOR INHIBITORS | TBXA2R, GP6, P2RY6 | EPHX2 3266/4885CNR1 253/4885SMN1; SMN2 3093/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.